Wang, Cun

circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity

Li, B., Zhu, L., Lu, C., Wang, C., Wang, H., Jin, H., Ma, X., Cheng, Z., Yu, C., Wang, S., et al. (2021) · Nature Communications

Circular RNAs in diseasesCancer-related molecular mechanisms research

Cited by 697

Inducing and exploiting vulnerabilities for the treatment of liver cancer

Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature

Telomeres, Telomerase, and SenescenceHepatocellular Carcinoma Treatment and Prognosis

Cited by 427

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer

Wang, L., Leite de Oliveira, R., Wang, C., Fernandes Neto, J. M., Mainardi, S., Evers, B., Lieftink, C., Morris, B., Jochems, F., Willemsen, L., et al. (2017) · Cell Reports

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 224

The Cancer SENESCopedia: A delineation of cancer cell senescence

Jochems, F., Thijssen, B., De Conti, G., Jansen, R., Pogacar, Z., Groot, K., Wang, L., Schepers, A., Wang, C., Jin, H., et al. (2021) · Cell Reports

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 201

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut

Hepatocellular Carcinoma Treatment and PrognosisCancer-related Molecular Pathways

Cited by 107

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Feng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene

Protein Kinase Regulation and GTPase SignalingColorectal Cancer Treatments and Studies

Cited by 95

Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs

Dong, F., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X.-L., Li, J., Feng, M., Cai, Z.-W., et al. (2026) · eLife

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 2

Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs

Dong, F., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X.-L., Li, J., Feng, M., Cai, Z.-W., et al. (2024) · eLife

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 1

Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs

Dong, F., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X.-L., Li, J., Feng, M., Cai, Z.-W., et al. (2026) · eLife

Immune cells in cancerCancer Immunotherapy and Biomarkers

Cited by 1